Crinetics Pharmaceuticals (CRNX) investor relations material

Executive summary

• Achieved strong commercial launch of PALSONIFY, with 232 new patient enrollments, 263 unique prescribers, and $10.3 million in net product revenue in Q1 2026, reflecting rapid adoption and demand across patient segments.

• PALSONIFY is establishing itself as a new standard of care in acromegaly, with broad adoption, 70% of patients on reimbursed therapy at quarter-end, and expanding prescriber base.

• International expansion milestones include European Commission approval in April 2026, positive CHMP opinion in February 2026, JNDA submission in Japan, and MAA submission in Brazil.

• Deep clinical pipeline advancing, with four major trials actively enrolling, including atumelnant (Phase 2/3 EQUILIBRIUM in ADCS), CRN09682 for NETs, and BALANCE-CAH study initiated.

• Cash, cash equivalents, and investments totaled $1.3 billion as of March 31, 2026, supporting operations and strategic initiatives into 2030.

Financial highlights

• Total Q1 2026 revenue was $10.7 million, up from $6.2 million in Q4 2025, including $10.3 million from PALSONIFY and $0.4 million from a Japanese licensing agreement.

• R&D expenses rose to $100.1 million in Q1 2026 from $85.1 million in Q4 2025, reflecting ramp-up of phase III and pediatric studies.

• SG&A expenses were $50.8 million in Q1 2026, up from $35.5 million in Q1 2025.

• Net loss for Q1 2026 was $127.8 million, compared to $122.8 million in Q4 2025 and $96.8 million in Q1 2025.

• Completed a $380 million public equity offering in January 2026, boosting liquidity.

Outlook and guidance

• Maintains 2026 GAAP operating expense guidance of $600–$650 million and non-GAAP guidance of $480–$520 million.

• Cash runway projected to fund operations into 2030, supporting commercialization and pivotal trial readouts.

• Expects to exceed 75% PALSONIFY coverage by end of Q3 2026, with payer coverage already exceeding 60%.

• No international revenue expected in 2026; early launches planned for 2027.

• Anticipates further increases in R&D and SG&A expenses as pipeline advances and commercial activities expand.